AZN.L released more bad news over the week. Here's the gist:
Fri 4 Feb: "the agency [FDA] has accepted AstraZeneca's resubmission of the ticagrelor NDA [aka Brilinta], categorised it as a Class 2 resubmission to the CRL, and set a new PDUFA date of 20 July 2011." I don't that came as a surpise to anyone.
Mon 7 Feb: AZN buys 750k of its own shares, at 2942pps. That's about £22m.
Mon 7 Feb: "ASTRAZENECA HALTS PHASE III TRIAL OF ZIBOTENTAN". So basically, it doesn't work.
It was interesting to see that AZN was up 2% today, against the Footsie of 0.7%. Over the last 5 days, AZN is up 3.1%, compared to the Footsie up 1.9%. Perhaps I'm being premature and overoptimistic, but could we be seeing that AZN is an exhausted bear? I could be wrong, of course; in which case, expect me to make more predictions in the hope of improving my hit rate.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment